Acrivon Therapeutics, Inc.'s Quiet Period To End on December 26th (NASDAQ:ACRV)
Acrivon Therapeutics, Inc.'s Quiet Period To End on December 26th (NASDAQ:ACRV)
Acrivon Therapeutics' (NASDAQ:ACRV – Get Rating) quiet period is set to end on Monday, December 26th. Acrivon Therapeutics had issued 7,550,000 shares in its IPO on November 15th. The total size of the offering was $94,375,000 based on an initial share price of $12.50. During Acrivon Therapeutics' quiet period, insiders and underwriters involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.
阿里冯治疗公司(纳斯达克代码:ACRV-GET Rating)的静默期将于12月26日(星期一)结束。Acrivon治疗公司在11月15日的首次公开募股中发行了7,550,000股票。根据12.50美元的初始股价,此次发行的总规模为94,375,000美元。在阿里冯治疗公司的静默期内,由于美国证券交易委员会的监管规定,参与首次公开募股的内部人士和承销商被限制发布任何研究报告或对公司的收益预期。在该公司的静默期结束后,作为承销商的券商可能会启动对该公司的研究报道。
Analyst Upgrades and Downgrades
分析师升级和下调评级
Several research analysts have issued reports on the stock. Cowen assumed coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They issued an "outperform" rating on the stock. Piper Sandler assumed coverage on shares of Acrivon Therapeutics in a research report on Sunday, December 11th. They issued an "overweight" rating and a $25.00 price target on the stock. Cowen assumed coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They issued an "outperform" rating on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Acrivon Therapeutics in a research report on Monday, December 12th. They issued a "buy" rating and a $17.00 price target on the stock.
几位研究分析师已经发布了关于该股的报告。考恩在12月12日星期一的一份研究报告中对Acrivon Treeutics的股票进行了报道。他们对该股给予了“跑赢大盘”的评级。派珀·桑德勒在12月11日周日的一份研究报告中对Acrivon Treeutics的股票进行了报道。他们对该股给予了“增持”评级和25.00美元的目标价。考恩在12月12日星期一的一份研究报告中对Acrivon Treeutics的股票进行了报道。他们对该股给予了“跑赢大盘”的评级。最后,杰富瑞金融集团在12月12日星期一的一份研究报告中对Acrivon治疗公司的股票进行了报道。他们对该股给予了“买入”评级和17.00美元的目标价。
Acrivon Therapeutics Price Performance
Acrivon治疗药物性价比
Acrivon Therapeutics stock opened at $11.99 on Monday. Acrivon Therapeutics has a 52 week low of $10.90 and a 52 week high of $20.70.
Acrivon治疗公司的股票周一开盘报11.99美元。Acrivon Treeutics的52周低点为10.90美元,52周高点为20.70美元。
Insider Activity
内幕活动
About Acrivon Therapeutics
关于Acrivon治疗公司
(Get Rating)
(获取评级)
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to specific medicine by utilizing its proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3).
Acrivon治疗公司是一家临床阶段的生物制药公司,该公司致力于开发精确肿瘤学药物,通过利用其基于蛋白质组学的患者响应者识别平台Acrivon Predictive Precision Protetics(AP3),将其与预测其肿瘤对特定药物敏感的患者相匹配。
Read More
阅读更多内容
- Get a free copy of the StockNews.com research report on Acrivon Therapeutics (ACRV)
- Is it Time to Take a Bite into Domino's Pizza?
- MarketBeat: Week in Review 12/12 – 12/16
- Which Two Bluechip Tech Companies Have Raised Their Guidance?
- Should You Worry About Elon Musk Selling His Tesla Shares?
- Can Tractor Supply Stock Surge Past Cup-With-Handle Buy Point?
- 免费获取StockNews.com关于Acrivon治疗公司(ACRV)的研究报告
- 是时候去Domino‘s Pizza尝一口了吗?
- MarketBeat:回顾一周12/12-12/16
- 哪两家蓝筹科技公司提高了他们的指引?
- 你应该担心埃隆·马斯克出售他持有的特斯拉股票吗?
- 拖拉机库存能否突破杯柄收购点?
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得Acrivon治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acrivon Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。
译文内容由第三方软件翻译。